Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

NCT02785952 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

275

Enrollment

NETWORK

Sponsor class

Conditions

Recurrent Squamous Cell Lung Carcinoma
Stage IV Squamous Cell Lung Carcinoma AJCC v7

Interventions

BIOLOGICAL: Ipilimumab
OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Nivolumab
OTHER: Quality-of-Life Assessment
OTHER: Questionnaire Administration

Sponsor

SWOG Cancer Research Network

Collaborators

[object Object]